2011
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis
Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW, Investigators H. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. Journal Of The American College Of Cardiology 2011, 57: 2309-2316. PMID: 21636031, DOI: 10.1016/j.jacc.2011.01.038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMajor bleedingMyocardial infarctionCardiac mortalityAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsPrimary Percutaneous Coronary Intervention ResultsGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsElevation myocardial infarction patientsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBenefit of bivalirudinLate cardiac survivalProbable stent thrombosisPercutaneous coronary interventionTwo-year rateAcute myocardial infarctionMyocardial infarction patientsHORIZONS-AMISwitch patientsPrimary angioplastyControl patientsCoronary interventionPROGNOSTIC IMPACT OF STAGED VERSUS “ONE-TIME” MULTIVESSEL PCI IN ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: LONG-TERM ANALYSIS FROM THE HORIZONS-AMI TRIAL
Kornowski R, Mehran R, Dangas G, Assali A, Nikolsky E, Gersh B, Wong S, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky A, Stone G. PROGNOSTIC IMPACT OF STAGED VERSUS “ONE-TIME” MULTIVESSEL PCI IN ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: LONG-TERM ANALYSIS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1653. DOI: 10.1016/s0735-1097(11)61653-7.Peer-Reviewed Original ResearchAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction
2009
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implications
2007
Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial)
Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW. Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial). The American Journal Of Cardiology 2007, 100: 206-210. PMID: 17631071, DOI: 10.1016/j.amjcard.2007.02.080.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary PCIMyocardial blush gradeCongestive heart failurePercutaneous coronary interventionMyocardial infarctionNondiabetic patientsDiabetes mellitusInfarct sizeMyocardial perfusionBlush gradeCoronary interventionHeart failureMyocardial reperfusionDiabetic patientsAcute ST-segment elevation myocardial infarctionST-segment elevation acute myocardial infarctionFinal myocardial blush gradeVersus Without Diabetes MellitusElevation acute myocardial infarctionSevere congestive heart failureDistal embolic protectionFinal infarct size
2006
Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial)
Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O’Neill W, Lansky AJ, Griffin JJ, Investigators C. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2006, 98: 331-337. PMID: 16860018, DOI: 10.1016/j.amjcard.2006.01.102.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexStentsStroke VolumeSurvival RateTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIMyocardial Infarction (TIMI) grade 3 flowIschemic target vessel revascularizationGrade 3 flowOutcomes of patientsTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationAcute MICoronary interventionMyocardial infarctionAcute ST-segment elevation myocardial infarctionSegment elevation acute myocardial infarctionMajor adverse cardiac eventsElevation acute myocardial infarctionOngoing chest painSimilar late mortalityAdverse cardiac eventsElevation myocardial infarctionST-segment elevationAcute myocardial infarctionHigher ejection fractionPostprocedural Thrombolysis
2005
Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial
Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R, Investigators F. Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial. JAMA 2005, 293: 1063-1072. PMID: 15741528, DOI: 10.1001/jama.293.9.1063.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPercutaneous coronary interventionST-segment resolutionAcute ST-segment elevation myocardial infarctionMajor adverse cardiac eventsAdverse cardiac eventsEvent-free survivalElevation myocardial infarctionDistal protectionInfarct sizeMyocardial infarctionCardiac eventsCoronary interventionReperfusion successBalloon occlusionEmergent percutaneous coronary interventionComplete ST-segment resolutionPrimary percutaneous coronary interventionEnd pointDistal balloon occlusionDistal embolic protectionPrimary PCI resultsCoprimary end pointsSecondary end pointsAcute myocardial infarction